The Food and Drug Administration (FDA) is reviewing an ER formulation of alfuzosin hydrochloride 10 mg for once-daily administration for treatment of symptomatic BPH. The IR and twice-daily ER ...

This randomized, double-blind, placebo-controlled study was conducted at 52 sites in the United States from 10 January 2003 to 18 August 2003. An amendment to the original study protocol, made on 22 ...

Alfuzosin is available as a generic drug and as a brand-name drug. Brand name: Uroxatral. Alfuzosin only comes as an extended-release oral tablet. Alfuzosin is used to treat benign prostatic ...

To better determine the onset of symptom relief with alfuzosin 10 mg q.d. in men with symptomatic BPH, we conducted a short-term, randomized, controlled clinical trial. For this investigation, we used ...

Sun Pharmaceutical Industries today said it has received the US health regulator's nod to market Alfuzosin Hydrochloride tablets, used in the treatment of prostatic hyperplasia, in the American market ...

Mylan has begun shipment of Alfuzosin HCl extended-release tablets, the generic version of Uroxatral (sanofi aventis), a treatment for signs and symptoms of benign prostatic hyperplasia. Alfuzosin HCl ...

Wockhardt announced that it has received final approval from the FDA for Alfuzosin HCl Extended-Release Tablets, the generic version of Sanofi-Aventis‘ Uroxatral. Alfuzosin HCl is an α 1-blocker ...

The dosage of IR alfuzosin hydrochloride ranges from 2.5 mg p.o. thrice daily to a maximum of 10-12 mg/day. Frequent daily administration is required because of alfuzosin's short serum half-life.

Sun Pharmaceutical Industries on Tuesday said it has received the US health regulator's nod to market Alfuzosin Hydrochloride tablets, used in the treatment of prostatic hyperplasia, in the American ...

Sun Pharmaceutical Industries Ltd today said it has received the US health regulator’s nod to market Alfuzosin Hydrochloride tablets, used in the treatment of prostatic hyperplasia, in the American ...